氯沙坦氢氯噻嗪合剂治疗血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者疗效研究

目的：研究应用氯沙坦氢氯噻嗪合剂治疗血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者的治疗效果及安全性。方法：选取2010年1月至2012年12月间在我院治疗的80例服用血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者作为研究对象,采用氯沙坦钾氢氯噻嗪片对患者进行治疗,每日1片（含氯沙坦钾50mg,氢氯噻嗪12.5mg）,晨起顿服。疗程共8周,治疗过程中监测患者血压、心率、血糖、血脂、电解质、血尿酸、肝肾功能等指标,以评价药物的治疗效果及安全性。结果：80例患者中,共75例完成治疗,治疗后患者平均血压由163.4±9.8/107.5±8.7（收缩压/舒张压）下降到137.4±8.3/88.7±7.8,血压控制率达77.3%;实验中患者未出现低钾血症等严重不良反应,仅1例患者因头晕退出治疗,不良反应发生率为1.3%。结论：氯沙坦氢氯噻嗪合剂对血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者具有显著疗效,且安全可靠。

Observation on the Clinical Efficacy of Losartan Potassium and Hydrochlorothiazide in Treating Hypertensive Patients Ineffective Controlled by Angiotensin Receptor Blockers

Objective： To observe the clinical efficacy of losartan hydrochlorothiazide mixture in treating hypertensive patients ineffective controlled by angiotensin receptor blockers. Method： Selected 80 patients ineffective controlled by angiotensin receptor blockers who received treatment in our hospital from Jan. 2010to Dec. 2012 for experiment objects. Losartan potassium and hydrochlorothiazide tablets was received 1 tablet per day to control their blood pressure. The treatment lasted 8 weeks,and the blood pressure,heart rate,blood glucose,blood lipids,electrolytes,uric acid,liver and renal function were monitored to evaluate the clinical efficacy and safety. Result： Of all the patients,75 cases finished the treatment,the blood pressure decreased from 163.4±9.8 /107.5±8.7 mmHg（ SBP / DBP） to 137.4±8.3 /88.7±7.8 mmHg,blood pressure control rates was 77.3%,no adverse reaction was observed,and only 1 patient（ 1.3%） quitted for headache.Conclusion： Losartan potassium and hydrochlorothiazide tablets is very effective and safe in treating hypertensive patients ineffective controlled by angiotensin receptor blockers.